HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis.

In a combined analysis of anti-IFN-β levels for DR4-positive and DR4-negative carriers of validation and study groups, a highly significant elevation of anti-IFN-β levels was found in carriers of DR4 alleles (median reactivity = 55.1%, p value ≤ 0.01) ( Figure 1 ).

also in 132,142 other papers